Benjamin Pelcman

This inventor holds 27 USPTO granted patents and 31 published patent applications, plus 1 CIPO patent and 10 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Atrogi Ab, Boehringer Ingelheim International Gmbh, Oblique Therapeutics Ab. Active years: 2000-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Benjamin Pelcman. Retrieved from https://idiyas.com/inventor/benjamin-pelcman

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 27 (Patent Applications = 31)

% Patents Active = 51.9

CIPO Patents = 1 (Patent Applications = 14)

EPO Patents = 10 (Patent Applications = 34)

Average Co-Inventor Count = 3.0

ph-index = 6

Forward Citations = 126(Granted Patents)

Location History:

Solna, SE (2010 - 2012)
Uppsala, SE (2014 - 2015)
Stockholm, SE (2000 - 2024)

Company Filing History:

Boehringer Ingelheim International Gmbh

patents

4 out of 8

Oblique Therapeutics Ab

patents

4. 3 out of 14

Astrazeneca Canada Inc.

Abbott Laboratories Corporation

where one patent can have more than one assignee

Years Active: 2000-2025

Loading Chart...

Areas of Expertise:

Hyperglycaemia

Cancer Treatment

Anti-Inflammatory Agents

Beta-Hydroxyethylamines

Pyridines

Piperazinyl Pyrazines

Analgesic Compounds

Heteroaryl Compounds

Sulfonyl-Substituted

Indoles

Chiral Compounds

Prostaglandin Inhibitors

27 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12378216 - Heteroaryl(heterocyclyl)methanol compounds useful in the treatment of hyperglycaemia (2025-08-05),

2. 12280023 - Fluorophenyl beta-hydroxyethylamines and their use in the treatment of hyperglycaemia (2025-04-21),

3. 12036210 - Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycaemia (2024-07-16),

4. 11793774 - Chiral beta-hydroxyethylamines and their use in the treatment of hyperglycemia (2023-10-24),

5. 11648216 - Fluorophenyl beta-hydroxyethylamines and their use in the treatment of hyperglycaemia (2023-05-16),

6. 11427539 - Beta-hydroxy heterocyclic amines and their use in the treatment of hyperglycaemia (2022-08-30),

7. 11357757 - Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycaemia (2022-06-14),

8. 11208384 - Sulfinylpyridines and their use in the treatment of cancer (2021-12-28),

9. 11168069 - Heterocyclylsulfonyl-substituted pyridines and their use in the treatment of cancer (2021-11-09),

10. 11161815 - Hydrocarbylsulfonyl-substituted pyridines and their use in the treatment of cancer (2021-11-02),

11. 11028067 - Heteroarylsulfonyl-substituted pyridines and their use in the treatment of cancer (2021-06-08),

12. 8951999 - Compounds (2015-02-10),

13. 8921405 - Compounds (2014-12-30),

14. 8759537 - 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents (2014-06-24),

15. 8586604 - Inhibitors of the microsomal prostaglandin E2 synthase-1 (2013-11-19),

Title: The Innovative Path of Benjamin Pelcman: Pioneering Treatments for Hyperglycemia

Introduction:

Benjamin Pelcman is a notable inventor based in Stockholm, SE, renowned for his groundbreaking work in the field of pharmaceuticals. With a prolific career marked by 25 patents to his name, Pelcman has made significant contributions to the medical industry.

Latest Patents:

Pelcman's recent patents showcase his focus on developing treatments for hyperglycemia. His inventions include "Heteroaryl substituted beta-hydroxyethylamines for use in treating hyperglycaemia" and "Chiral beta-hydroxyethylamines and their use in the treatment of hyperglycemia." These compounds offer promising solutions for managing this prevalent medical condition.

Career Highlights:

Throughout his career, Pelcman has held positions at esteemed companies such as Atrogi AB and Boehringer Ingelheim International GmbH. His tenure at these organizations has allowed him to leverage his expertise in pharmaceuticals and drive innovation in the field.

Collaborations:

Pelcman's collaborative spirit is evident in his professional interactions with coworkers like Edgars Suna and Henning Priepke. Together, they have worked on projects that have pushed the boundaries of pharmaceutical research and development.

Conclusion:

Benjamin Pelcman's innovative drive and dedication to advancing medical treatments have solidified his reputation as a pioneering inventor in the realm of pharmaceuticals. His patented inventions stand as a testament to his commitment to addressing critical healthcare challenges, particularly in the realm of hyperglycemia treatment.

Profile summary based on public USPTO records.